CoChat
Sign Up
Cited by 401Folate and B Vitamins ResearchPregnancy and preeclampsia studiesReproductive System and Pregnancy

The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.

Folic Acid and Homocyst(e)ine Metabolic Defects and the Risk of Placental Abruption, Pre-eclampsia and Spontaneous Pregnancy Loss: A Systematic Review

Ray, J.G, Laskin, C.A·1999·Placenta
DOI 10.1053/plac.1999.0417
Open this paper in CoChat — free account

Abstract

Placental infarction or abruption, recurrent pregnancy loss and pre-eclampsia are thought to arise due to defects within the placental vascular bed. Deficiencies of vitamin B12 and folate, or other abnormalities within the methionine-homocyst(e)ine pathway have been implicated in the development of such placental diseases. We conducted a systematic literature review to quantify the risk of placental disease in the presence of these metabolic defects. Studies were identified through OVID Medline between 1966 and February 1999. Terms relating to the measurement of vitamin B12, folic acid, methylenetetrahydrofolate reductase or homocyst(e)ine were combined with those of pre-eclampsia, placental abruption/infarction or spontaneous and habitual abortion. Human studies comprising both cases and controls and published in the English language were accepted. Their references were explored for other publications. Data were abstracted on the matching of cases with controls, the mean levels of folate, B12 or homocyst(e)ine in each group or the frequency of the homozygous state for the thermolabile variant of methylenetetrahydrofolate reductase. The definition of 'abnormal' for each exposure was noted and the presence or absence of the exposure of interest for each outcome was calculated as an absolute rate with a 95 per cent confidence interval. The crude odds ratios were calculated for each study and then pooled using a random effects model. Eighteen studies were finally included. Eight studies examined the risk of placental abruption/infarction in the presence of vitamin B12 or folate deficiency, or hyperhomocyst(e)inaemia. Folate deficiency was a prominent risk factor for placental abruption/infarction among four studies, though not statistically significant (pooled odds ratio 25.9, 95 per cent CI 0.9-736.3). Hyperhomocyst(e)inaemia was also associated with placental abruption/infarction both without (pooled odds ratio 5.3, 95 per cent CI 1.8-15.9) and with methionine loading (pooled odds ratio 4.2, 95 per cent CI 1.2-15.0), as was the homozygous state for methylenetetrahydrofolate reductase (pooled odds ratio 2.3, 95 per cent CI 1.1-4.9). Vitamin B12 deficiency was not a demonstrable risk factor. Eight studies examined blood levels among women with spontaneous abortion or recurrent pregnancy loss. The pooled odds ratios were 3.4 (95 per cent CI 1.2-9.9) for folate deficiency, 3.7 (95 per cent CI 0.96-16.5) for hyperhomocyst(e)inaemia following methionine challenge, and 3.3 (95 per cent CI 1.2-9.2) for the methylenetetrahydrofolate reductase mutation. Five case-control studies examined the relationship between pre-eclampsia and abnormal levels of vitamin B12, folate, homocyst(e)ine or methylenetetrahydrofolate reductase. Folate deficiency was not an associated risk factor (odds ratio 1.2, 95 per cent CI 0.5-2.7), but hyper-homocyst(e)inaemia was (pooled odds ratio 20.9, 95 per cent CI 3.6-121.6). Similarly, homozygosity for the methylenetetrahydrofolate reductase thermolabile variant was associated with a moderate risk of preeclampsia (odds ratio 2.6, 95 per cent CI 1.4-5.1). Some pooled data were associated with significant statistical heterogeneity, however. There is a general agreement among several observational studies that folate deficiency, hyperhomocyst(e)inaemia and homozygosity for the methylenetetrahydrofolate reductase thermolabile variant are probable risk factors for placenta-mediated diseases, such as pre-eclampsia, spontaneous abortion and placental abruption. Vitamin B12 deficiency is less well defined as an important risk factor. Due to the limited quality of these data, including insufficient matching of cases with controls, and possible laboratory measurement bias relating to pregnancy, prospective studies are needed to confirm these findings and guide future preventative and therapeutic research.

Overview

Integrity signals

Registry

Crossref · 10.1053/plac.1999.0417

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

1 of the 75 references couldn’t be matched to a known paper.

Research works printed but not linked: 5

  1. Daly, 1998, The influence of 5′10 methylenetetrahydrofolate reductase genotypes on enzyme activity in placental tissue (Abstract), Am J Obstet Gynecol, 178, S23
  2. Hague, 1998, South Australian experience with hyperhomocysteinaemia as a risk factor in obstetrics. Time for a trial? (Abstract), Neth J Med, 24
  3. Hague, 1998, Prevention of recurrent pre-eclampsia by folic acid supplementation in women with hyperhomocysteinemia: proposal for a randomized controlled trial, Neth J Med, 52, 24
  4. Nelen, 1998, Association between chorionic villous vascularization and homocysteine concentration in women with unexplained recurrent pregnancy loss?, Neth J Med, 52, 57
  5. Van der Molen, 1998, The mutation 677C→T of the methylenetetrahydrofolate reductase (MTHFR) gene as a possible risk factor for placental vasculopathy, Neth J Med, 52, 28

Cited by

Sorted by citations

See all 401

Related

See all

Metadata

Authors
Ray, J. G., & Laskin, C. A.
Affiliations
University of Toronto (CA)
ORCID
Venue
Placenta
Publisher
Elsevier BV
Published
1999-09
Volume
20
Issue
7
Pages
519-529
ISSN
0143-4004 (ISSN-L)
DOI
10.1053/plac.1999.0417
OpenAlex
W2090474126
Cited by
401
References
75
Citations by year
2026: 1 · 2025: 5 · 2024: 5 · 2023: 8 · 2022: 11 · 2021: 11 · 2020: 7 · 2019: 12 · 2018: 8 · 2017: 11 · 2016: 14 · 2015: 21 · 2014: 10 · 2013: 19 · 2012: 13
FWCI
3.02
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Placenta (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Folate and B Vitamins Research
  • Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies
  • Life Sciences › Immunology and Microbiology › Immunology › Reproductive System and Pregnancy
Keywords
vitamin B12 deficiency, methylenetetrahydrofolate reductase, placental abruption, placental infarction, preeclampsia, miscarriage, recurrent pregnancy loss
MeSH terms
Abortion, Spontaneous, Abortion, Habitual, Abruptio Placentae, Female, Folic Acid Deficiency, Homocysteine, Humans, Infarction, Placenta, Pre-Eclampsia, Pregnancy, Pregnancy Complications, Risk Factors, Odds Ratio, Hyperhomocysteinemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review